Nachrichten zur IQ-AI LTD. LS -,01 Aktie

IQ-AI subsidiary Imaging Biometrics expands GE partnership, adds board member

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) earlier this week announced an expanded partnership between its subsidiary, Imaging Biometrics, and GE Healthcare. The...…

IQ-AIs Imaging Biometrics extends GE partnership

Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has extended its partnership with GE HealthCare to broaden access to its...…

IQ-AI files of patent and updates on trading and clinical trial

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) has filed a provisional application with the US Patent and Trademark Office for using Gallium Maltolate as a…

IQ-AI nearing a pivotal stage in the development of cancer treatment

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said it is nearing the completion of its phase I clinical trial of its IB003 cancer treatment with only…

IQ-AI approaching end of phase 1 trial of cancer treatment trial

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said its Phase 1 Clinical Trial for IB003, its gallium maltolate childrens brain cancer treatment, is in…

IQ-AI approaching end of phase 1 of cancer treatment trial

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said its Phase 1 Clinical Trial for IB003, its gallium maltolate childrens brain cancer treatment, is in…

IQ-AI subsidiary receives US access programme approval for brain cancer treatment

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics has received approval for an Expanded Access Program (EAP) for oral gallium maltolate…

IQ-AI Ltd says major East Coast cancer centre to use its technology

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said a US cancer centre has adopted IB Nimble for its Brain Metastases Program of Excellence. IB Nimble,…

IQ-AI boosted with second FDA rare pediatric disease designation for GaM

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) told investors that its subsidiary, Imaging Biometrics, has received a second US FDA Rare Pediatric Disease…

IQ-AI software installed by Swiss hospital group

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)s subsidiary, Imaging Biometrics, has successfully installed its advanced imaging software at Insel Gruppe AG, a hospital...…

IQ-AI subsidiary wins FDA designation for lead drug candidate

Imaging Biometrics, a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has announced that the US Food and Drug Administration (FDA) has granted…

IQ-AI shares jump as therapy offered to brain tumour patients

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the medical technology and pharmaceutical company, saw its shares pop 5% after it revealed its subsidiary…

IQ-AI raises £371,000 through broker option and placing

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) has successfully raised £371,000 before expenses through the issuance of 20 million new ordinary shares at 1.5p…

IQ-AI subsidiary Imaging Biometrics to resubmit PRD application to FDA

Imaging Biometrics, a wholly owned subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), intends to modify and resubmit its application for Paediatric…

IQ-AIs Imaging Biometrics launching Oral GaM expanded access program

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) has announced that its wholly owned subsidiary Imaging Biometrics is launching an intermediate population cohort expanded...…

IQ-AI announces positive results in ongoing GaM study

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), through its subsidiary Imaging Biometrics, has reported encouraging interim results from a Phase 1 study on…

IQ-AI applies for FDA pediatric rare disease designation

Imaging Biometrics, a wholly owned subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has submitted a pediatric rare disease (PRD) request to…